Prof LYU Aiping (LU Aiping)

  • Dean of Chinese Medicine; Dr. Kennedy Y.H. Wong Endowed Professor in Chinese Medicine; Director, Shum Yiu Foon Shum Bik Chuen Memorial Centre for Cancer & Inflammation Research; Director, Institute of Integrated Bioinformedicine and Translational Science; Director, Hong Kong Baptist University Joint Centre for Pain Research
  • Expert in Chinese Medicine, Clinical Pharmacology and Arthritis and related new drug discovery
  • aipinglu@hkbu.edu.hk

Professor Lyu Aiping is Chair Professor & Dean of School of Chinese Medicine, Hong Kong Baptist University, Director of Shum Yiu Foon Shum Bik Chuen Memorial Centre for Cancer & Inflammation Research (CCIR) of HKBU, Director of Institute of Integrated Bioinformedicine & Translational Science (IBTS) of HKBU, Director of Hong Kong Baptist University Joint Centre for Pain Research (JCPR), Chair Professor in China Academy of Chinese Medical Sciences (CACMS) and Recipient of the Distinguished Young Scholar in National Science Foundation of China (NSFC) in 2007. Prof. Lyu is also the member of Hong Kong Chinese Medicine Development Committee, the member of Hong Kong Chinese Medicine Administration Committee, the member of Biology and Medicine Panel in Hong Kong Research Grant Committee (RGC).

He obtained his bachelor degree from Jiangxi University of Traditional Chinese Medicine in 1983, and further obtained his master's and Ph.D. degrees from China Academy of Traditional Chinese Medicine (now called the China Academy of Chinese Medical Sciences, CACMS). From 2006 to 2012, he was the Director of Institute of Basic Research in Clinical Medicine, and the Director of Institute of Basic Theory of CACMS from 1999 to 2002. In 2002-2006, Prof Lyu was appointed as General Director, Jiangxi Herbfine Hi-tech Co. Ltd (National Pharmaceutical Engineering Centre), one of four centres in China in the field of Traditional Chinese Medicine industry.

His research interests mainly focus on the translational research in Chinese medicine, including pharmacological and clinical evaluation on rheumatoid arthritis with re-classification and interventions, and development of new drugs based on Chinese medicines. Also he is actively involving the research on the standardization of Chinese medicine and strategic plan research for Chinese medicine development in China.

Professor Lyu is a world-leading scientist in aptamer-based translational medicine and drug discovery.  He is not only working on basic research that demonstrates novel precision medicine-based therapeutic strategies for rheumatic disease treatment, but also on translational research in collaboration with pharmaceutical industry for the development of novel therapeutic agents. He is the director of the first aptamer R&D platform in Guangdong-Hong Kong-Macao Greater Bay Area of China, which has attracted aptamer pharmaceutical industries to establish "Aptamer Drug Valley" in the Hong Kong Science Park. He has developed the world's first ever osteoblast-targeting nucleic acid aptamer. His first discovery of the therapeutic aptamer targeting Sclerostin loop3 has been granted Orphan Drug Designation by US FDA (DRU-2019-6966) for evaluating the therapeutic potential for promoting bone formation in osteogenesis imperfect. He has also developed the first aptamer-Paclitaxel conjugates, which showcased a precision medicine-based personalized Paclitaxel for targeting specific cancer types, which is currently being developed into anti-cancer therapeutics by a pharmaceutical company.

Professor Lyu initiated the idea of using systems biology approach to identify metabolite biomarkers for subtyping RA patients with distinct clinical manifestations. His clinical research has also underpinned the potent efficacy of Tripterygium wilfordii Hook F. based therapy for RA treatment, which is recommended by the Chinese Association of Integrative Medicine as the Evidence-based Clinical Practice Guidelines. Besides, Professor Lyu has established the China's largest biobank of rheumatic diseases in Shanghai Guanghua Hospital of Integrative Medicine. The biobank has facilitated his discovery of the molecular mechanism addressing the limited efficacy of Leflunomide on bone erosion in a subgroup of RA patients with elevated serum C-reactive protein.

Prof Lyu has more than 600 publications with Google Scholar H index 66, i10-index 370 and a total of over 18000 citations. Over the years, he obtained more than 60 patents from his research activities.

Being a renowned expert and academic in the field, Prof Lyu has been appointed as Head & Spokesperson of the China Delegation, International Organization for Standardization Technical Committee on TCM (ISO/TC249) since 2009.  Besides, he also currently serves as Member of Medical Advisory Committee of National Natural Science Foundation of China (NSFC), Member of Chinese Pharmacopoeia Commission and Vice-Chairman, Terminology of Traditional Chinese Medicine Sub-Committee, China National Committee for Terms in Sciences and Technologies (CNCTST). Also he is the director of Chinese Medicine Standardization Office in State Administration of Traditional Chinese Medicine (SATCM), and the director of Chinese Medicine Standard Research Center in CACMS.

He was invited to serve as Visiting Scholar in a number of institutions including Lund University in Sweden, Ohio State University in the United States, Hong Kong Polytechnic University and Hong Kong University of Science and Technology. Based on his outstanding research achievement, Prof Lyu was invited as guest speakers in various international academic conferences.

Selected Publications

Representative Publications:

  • DDInter: an online drug-drug interaction database towards improving clinical decision-making and patient safety. Nucleic Acids Res. 2021 Oct 11:gkab880. doi: 10.1093/nar/gkab880
  • Exosomal transfer of osteoclast-derived miRNAs to chondrocytes contributes to osteoarthritis progression. Nature Aging, 2021 Apr 15;1, 368-384.doi.org/10.1038/s43587-021-00050-6
  • Improving structure-based virtual screening performance via learning from scoring function components. Brief Bioinform. 2021 May 20;22(3):bbaa094. doi: 10.1093/bib/bbaa094
  • Identifying Transcription factor combinations to modulate circadian rhythms by leveraging virtual knockouts on transcription networks. iScience. 2020 Aug 22;23(9):101490. doi: 10.1016/j.isci.2020.101490
  • Imperatorin and β-sitosterol have synergistic activities in alleviating collagen-induced arthritis. J Leukoc Biol. 2020 Aug;108(2):509-517. doi: 10.1002/JLB.3MA0320-440RR
  • HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis. Nat Commun. 2019 Oct 8;10(1):4579. doi: 10.1038/s41467-019-12163-z
  • Efficacy of leflunomide combined with ligustrazine in the treatment of rheumatoid arthritis: prediction with network pharmacology and validation in a clinical trial. Chin Med. 2019 Aug 2;14:26. doi: 10.1186/s13020-019-0247-8.
  • Osteoblastic PLEKHO1 contributes to joint inflammation in rheumatoid arthritis. EBioMedicine. 2019 Mar; 41:538-555. doi: 0.1016/j.ebiom.2019.02.009
  • Inhibition of osteoblastic Smurf1 promotes bone formation in mouse models of distinctive age-related osteoporosis. Nat Commun. 2018 Aug 24;9(1):3428
  • Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide. Drug Deliv. 2018 Nov;25(1):256-266
  • A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nat Commun. 2017;8(1)
  • A newly identified lncRNA MAR1 acts as a miR-487b sponge to promote skeletal muscle differentiation and regeneration. J Cachexia Sarcopenia Muscle. 2018 Jun;9(3):613-626
  • Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat Commun. 2016 Mar 7;7:10872.
  • A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of microRNAs in osteoclasts. Biomaterials. 2015 Jun;52:148-60. doi: 10.1016/j.biomaterials.2015.02.007.
  • Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat Med. 2015 Mar;21(3):288-94. doi: 10.1038/nm.3791.
  • Identification of Characteristic Autoantibodies Associated With Deficiency Pattern in Traditional Chinese Medicine of Rheumatoid Arthritis Using Protein Chips. Front Pharmacol. 2019 Jul 10;10:755. doi: 10.3389/fphar.2019.00755
  • An integrative method to decode regulatory logics in gene transcription. Nat Commun. 2017;8(1)
  • Predicting and verifying outcome of Tripterygium wilfordii Hook F. based therapy in rheumatoid arthritis: from open to double-blinded randomized trial. Sci Rep. 2015 Apr 15;5:9700. doi:10.1038/srep09700.
  • The Crosstalk of Pathways Involved in Immune Response Maybe the Shared Molecular Basis of Rheumatoid Arthritis and Type 2 Diabetes. PLoS One. 2015 Aug 7;10(8):e0134990. doi: 10.1371/journal.pone.0134990.
  • Serum metabolic signatures of four types of human arthritis. J Proteome Res. 2013 Aug 2; 12 (8): 3769-79.
  • Expert consensus on the treatment of rheumatoid arthritis with Chinese patent medicines. J Altern Complement Med. 2013; 19(2):111-118.
  • Comparison of toxic reaction of Tripterygium wilfordii multiglycoside in normal and adjuvant arthritic rats. J Ethnopharmacol. 2011; 135(2):270-277.
  • Cold and heat pattern of rheumatoid arthritis in traditional Chinese medicine: distinct molecular signatures indentified by microarray expression profiles in CD4-positive T cell. Rheumatol Int. 2010 Jul 25.
  • The effects of triptolide on enteric mucosal immune responses of DBA/1 mice with collagen induced arthritis. Planta Medica.2006; 72,1268-1272.
  • Circadian rhythms on hypothalamic–pituitary–adrenal axis hormones and cytokines of collagen induced arthritis in rats. J Autoimmun. 2004; 22(4):277-85.
Top